Mesenchymal Stem Cells Contribute to the Abnormal Bone Marrow Microenvironment in Patients with Chronic Idiopathic Neutropenia by Overproduction of Transforming Growth Factor-β1

Stavroulaki, Emily; Kastrinaki, Maria-Christina; Pontikoglou, Charalampos; Damianaki, Athina; Mavroudi, Irene; Pyrovolaki, Katerina; Katonis, Pavlos; Papadaki, Helen Α.

doi:10.1089/scd.2010.0425

Cited by 16 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28] Cumulatively this work suggests that CIN is an immune-mediated bone marrow failure syndrome that impairs normal production of neutrophils in the bone marrow. [29]…”

Section: Disease Mechanismsmentioning

confidence: 99%

An update on the diagnosis and treatment of chronic idiopathic neutropenia

Dale¹,

Bolyard

2017

Current Opinion in Hematology

View full text Add to dashboard Cite

Purpose of Review Neutropenia lasting for at least for 3 months and not attributable to drugs or a specific genetic, infectious, inflammatory, autoimmune or malignant cause is called chronic idiopathic neutropenia. (CIN) CIN and autoimmune neutropenia (AIN) are very similar and overlapping conditions. The clinical consequences depend upon the severity of neutropenia, but it is not considered a premalignant condition. Recent findings Long-term observational studies in children indicate that the disease often lasts for 3 to 5 years in children, then spontaneously remits, but it rarely remits in adult cases. The value of anti-neutrophil antibody testing in both children and adults is uncertain. Most recent data suggest that CIN and AIN are immune mediated diseases, but there are no new clinical or genetic tests to aid in diagnosis. Treatment with granulocyte colony stimulating factor (G-CSF) is effective to increase blood neutrophils in almost all cases; this treatment is reserved, however for patients with both neutropenia and evidence of recurrent fevers, inflammatory symptoms and infections. There is little or no evidence to indicate that G-CSF treatment predisposes to myeloid malignancies in this population. Summary It is important to recognize CIN and AIN, the most common causes of chronic neutropenia in both children and adults. If the neutropenia is not severe, i.e. > 0.5 × 109/L, most patients can be observed and not treated prophylactically with antibiotics or a growth factor. When neutropenia is severe treatment with G-CSF is often beneficial.

show abstract

“…[28] Cumulatively this work suggests that CIN is an immune-mediated bone marrow failure syndrome that impairs normal production of neutrophils in the bone marrow. [29]…”

Section: Disease Mechanismsmentioning

confidence: 99%

An update on the diagnosis and treatment of chronic idiopathic neutropenia

Dale¹,

Bolyard

2017

Current Opinion in Hematology

View full text Add to dashboard Cite

show abstract

“…CIN-derived MSCs produce normal levels of TNF- α , IL-1 β , and IL-6 in culture supernatants, suggesting that BM MSCs are not responsible for the elevated levels in patient marrow. CIN-derived MSC immunosuppressive potential did not differ from normal MSCs, in terms of inhibition of mitogen-induced T cell proliferation [111]. …”

Section: Chronic Idiopathic Neutropeniamentioning

confidence: 99%

Mesenchymal Stem Cells in Immune-Mediated Bone Marrow Failure Syndromes

Kastrinaki

Pavlaki

Batsali

et al. 2013

Clinical and Developmental Immunology

Self Cite

View full text Add to dashboard Cite

Immune-mediated bone marrow failure syndromes (BMFS) are characterized by ineffective marrow haemopoiesis and subsequent peripheral cytopenias. Ineffective haemopoiesis is the result of a complex marrow deregulation including genetic, epigenetic, and immune-mediated alterations in haemopoietic stem/progenitor cells, as well as abnormal haemopoietic-to-stromal cell interactions, with abnormal release of haemopoietic growth factors, chemokines, and inhibitors. Mesenchymal stem/stromal cells (MSCs) and their progeny (i.e., osteoblasts, adipocytes, and reticular cells) are considered as key cellular components of the bone marrow haemopoietic niche. MSCs may interfere with haemopoietic as well as immune regulation. Evidence suggests that bone marrow MSCs may be involved in immune-mediated BMFS underlying pathophysiology, harboring either native abnormalities and/or secondary defects, caused by exposure to activated marrow components. This review summarizes previous as well as more recent information related to the biologic/functional characteristics of bone marrow MSCs in myelodysplastic syndromes, acquired aplastic anemia, and chronic idiopathic neutropenia.

show abstract

“…Leukaemic cells also overexpress VLA-4, an adhesion molecule which interacts with VCAM expressed in MSC. Therefore, it is proved that leukaemic cells interact with MSC and this interaction creates an abnormal microenvironment in the niche, thereby disrupting normal development of haematopoiesis [26,27].…”

Section: Bone Marrow Niches and Haematopoietic Tumorigenesismentioning

confidence: 99%

Mesenchymal niches of bone marrow in cancer

et al. 2011

View full text Add to dashboard Cite

Over the last decade, genetic and cell biology studies have indicated that tumour growth is not only determined by malignant cancer cells themselves, but also by the tumour microenvironment. Cells present in the tumour microenvironment include fibroblasts, vascular, smooth muscle, adipocytes, immune cells and mesenchymal stem cells (MSC). The nature of the relationship between MSC and tumour cells appears dual and whether MSC are pro- or anti-tumorigenic is a subject of controversial reports. This review is focused on the role of MSC and bone marrow (BM) niches in cancer.

show abstract

Mesenchymal Stem Cells Contribute to the Abnormal Bone Marrow Microenvironment in Patients with Chronic Idiopathic Neutropenia by Overproduction of Transforming Growth Factor-β1

Cited by 16 publications

References 35 publications

An update on the diagnosis and treatment of chronic idiopathic neutropenia

An update on the diagnosis and treatment of chronic idiopathic neutropenia

Mesenchymal Stem Cells in Immune-Mediated Bone Marrow Failure Syndromes

Mesenchymal niches of bone marrow in cancer

Contact Info

Product

Resources

About